Recent News

• 05.30.2025 - Adlai Nortye Announces Topline Results of Phase III BURAN Trial Evaluating Buparlisib (AN2025) in Combination with Paclitaxel for Recurrent or Metastatic HNSCC
• 05.30.2025 - Adlai Nortye Announces Topline Results of Phase III BURAN Trial Evaluating Buparlisib (AN2025) in Combination with Paclitaxel for Recurrent or Metastatic HNSCC
• 05.12.2025 - Adlai Nortye Reports Full Year 2024 Financial Results and Business Updates
• 05.12.2025 - Adlai Nortye Reports Full Year 2024 Financial Results and Business Updates
• 04.10.2025 - Adlai Nortye to Present Research Findings at AACR Annual Meeting 2025
• 04.10.2025 - Adlai Nortye to Present Research Findings at AACR Annual Meeting 2025
• 01.03.2025 - Xiaofeng (Alex) Ye, PhD
• 01.03.2025 - Xiaofeng (Alex) Ye, PhD

Recent Filings

• 05.30.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.12.2025 - 20-F/A Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
• 04.30.2025 - 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
• 04.29.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 02.27.2025 - UPLOAD SEC-generated letter
• 02.14.2025 - 20-F/A Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
• 02.14.2025 - EX-99.1 EX-99.1
• 02.14.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 01.27.2025 - CORRESP Correspondence
• 01.02.2025 - CORRESP Correspondence